Prognostic Factors for Uterine Sarcoma and Carcinosarcoma: Insights from a 10-Year Follow-Up Study

Beata Kotowicz; Anna Dańska-Bidzińska; Małgorzata Fuksiewicz; Anna Nasierowska-Guttmejer; Dorota Raczkiewicz; Mariusz Gujski; Szymon Piątek; Mariusz Bidziński

doi:10.12659/MSM.941562

07 December 2023 : Clinical Research

Prognostic Factors for Uterine Sarcoma and Carcinosarcoma: Insights from a 10-Year Follow-Up Study

Beata Kotowicz

^1ACDEF*, Anna Dańska-Bidzińska

^2ABDEG, Małgorzata Fuksiewicz

^1BCDE, Anna Nasierowska-Guttmejer

^3BC, Dorota Raczkiewicz

^4C, Mariusz Gujski

^5BEF, Szymon Piątek

^6B, Mariusz Bidziński

^6AEG

DOI: 10.12659/MSM.941562

Med Sci Monit 2023; 29:e941562

Authors information Article notes Copyright and License information

Background Material and Methods Results Discussion Conclusions References

Related articles Order reprints Share article Share by email

View HTML version

Figure 1 Low-grade endometrial stroma sarcoma (LG ESS) staining with hematoxylin-eosin (A), high expression of ER (B), high expression of PR (C), high expression of Ki67 (D). Created using Windows 10Pro, PowerPoint.

Back to the Article

Prognostic Factors for Uterine Sarcoma and Carcinosarcoma: Insights from a 10-Year Follow-Up Study

Your Privacy